Logo image of ALTHX.PA

THX PHARMA SACA (ALTHX.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALTHX - FR0013286259 - Common Stock

2.02 EUR
-0.01 (-0.49%)
Last: 1/12/2026, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, ALTHX scores 1 out of 10 in our fundamental rating. ALTHX was compared to 53 industry peers in the Pharmaceuticals industry. ALTHX may be in some trouble as it scores bad on both profitability and health. ALTHX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALTHX has reported negative net income.
In the past year ALTHX has reported a negative cash flow from operations.
ALTHX had negative earnings in each of the past 5 years.
In the past 5 years ALTHX always reported negative operating cash flow.
ALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of ALTHX (-64.91%) is worse than 84.91% of its industry peers.
Industry RankSector Rank
ROA -64.91%
ROE N/A
ROIC N/A
ROA(3y)-65.38%
ROA(5y)-54.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTHX.PA Yearly ROA, ROE, ROICALTHX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

ALTHX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTHX.PA Yearly Profit, Operating, Gross MarginsALTHX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

ALTHX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALTHX has been increased compared to 5 years ago.
Compared to 1 year ago, ALTHX has a worse debt to assets ratio.
ALTHX.PA Yearly Shares OutstandingALTHX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALTHX.PA Yearly Total Debt VS Total AssetsALTHX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

ALTHX has an Altman-Z score of -0.76. This is a bad value and indicates that ALTHX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.76, ALTHX is not doing good in the industry: 75.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.76
ROIC/WACCN/A
WACCN/A
ALTHX.PA Yearly LT Debt VS Equity VS FCFALTHX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 0.93 indicates that ALTHX may have some problems paying its short term obligations.
ALTHX's Current ratio of 0.93 is on the low side compared to the rest of the industry. ALTHX is outperformed by 75.47% of its industry peers.
A Quick Ratio of 0.93 indicates that ALTHX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.93, ALTHX is in line with its industry, outperforming 45.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
ALTHX.PA Yearly Current Assets VS Current LiabilitesALTHX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.71% over the past year.
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1140%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALTHX will show a very strong growth in Earnings Per Share. The EPS will grow by 179.88% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.34%
EPS Next 2Y179.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTHX.PA Yearly Revenue VS EstimatesALTHX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2021 5M 10M 15M
ALTHX.PA Yearly EPS VS EstimatesALTHX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALTHX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 2.91, the valuation of ALTHX can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALTHX indicates a rather cheap valuation: ALTHX is cheaper than 100.00% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.98. ALTHX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 2.91
ALTHX.PA Price Earnings VS Forward Price EarningsALTHX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTHX.PA Per share dataALTHX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

ALTHX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALTHX's earnings are expected to grow with 179.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y179.88%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALTHX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

THX PHARMA SACA

EPA:ALTHX (1/12/2026, 7:00:00 PM)

2.02

-0.01 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-25 2025-09-25
Earnings (Next)N/A N/A
Inst Owners8.48%
Inst Owner ChangeN/A
Ins Owners10.12%
Ins Owner ChangeN/A
Market Cap27.88M
Revenue(TTM)N/A
Net Income(TTM)-2.94M
Analysts86.67
Price Target4.51 (123.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-124.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.91
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.69
Fwd EY34.32%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS-0.14
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.91%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.38%
ROA(5y)-54.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 172.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z -0.76
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.38%
Cap/Depr(5y)30.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1140%
EPS Next Y8.34%
EPS Next 2Y179.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.22%
OCF growth 3YN/A
OCF growth 5YN/A

THX PHARMA SACA / ALTHX.PA FAQ

What is the ChartMill fundamental rating of THX PHARMA SACA (ALTHX.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALTHX.PA.


Can you provide the valuation status for THX PHARMA SACA?

ChartMill assigns a valuation rating of 4 / 10 to THX PHARMA SACA (ALTHX.PA). This can be considered as Fairly Valued.


How profitable is THX PHARMA SACA (ALTHX.PA) stock?

THX PHARMA SACA (ALTHX.PA) has a profitability rating of 0 / 10.